How Does the COVID-19 Antiviral Medications Workflow Compare to the Traditional Antiviral Production Pipeline
As the COVID-19 pandemic continues to progress researchers and scientists are starting to learn more about the virus in order to effectively combat it. One of those lessons is how the COVID-19 virus compares to other viruses when it comes to developing treatments. Justin Honore talked to Dr. Kishor Wasan, PH.D.,FAAPS, FCAHS, FCSPS, Chief…
This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.
Get featured
Want to get featured in MarketScale Healthcare?
Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.
As the COVID-19 pandemic continues to progress researchers and scientists are starting to learn more about the virus in order to effectively combat it. One of those lessons is how the COVID-19 virus compares to other viruses when it comes to developing treatments. Justin Honore talked to Dr. Kishor Wasan, PH.D.,FAAPS, FCAHS, FCSPS, Chief Medical & Scientific Officer at Skymount Medical and a Distinguished University Scholar Adjunct Professor at the University of British Columbia about how COVID-19 vaccine research and production compare to the traditional antiviral and antibiotic production pipeline.
Your experts belong here
Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.
Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.
